Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Antigen specificities and proviral integration sites differ in HIV-infected cells by timing of antiretroviral treatment initiation.

The Journal of clinical investigation·2024

Same author

Author Correction: Elevated body temperature is associated with depressive symptoms: results from the TemPredict Study.

Scientific reports·2024

Same author

Utilizing Wearable Device Data for Syndromic Surveillance: A Fever Detection Approach.

Sensors (Basel, Switzerland)·2024

Same author

Expert consensus on nutrition and lower-carbohydrate diets: An evidence- and equity-based approach to dietary guidance.

Frontiers in nutrition·2024

Same author

Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.

AIDS (London, England)·2024

Same author

Sedentary Behavior and Dementia.

JAMA·2024

Search research articles

Related Experiment Video

Updated: May 30, 2026

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

Identifying the early post-HIV antibody seroconversion period.

Frederick M Hecht¹, Robert Wellman, Michael P Busch

¹University of California, San Francisco, CA, USA. rhecht@php.ucsf.edu

The Journal of Infectious Diseases

|July 28, 2011

Summary

Identifying recent human immunodeficiency virus (HIV) infections is crucial. Antibody-based tests like EIAs, Western blots, and incidence assays show varying accuracy for detecting HIV seroconversion within 90 days.

More Related Videos

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

Detection of Rabies IgG and IgM Antibodies Using the Rabies Indirect Fluorescent Antibody Test

Detection of Rabies IgG and IgM Antibodies Using the Rabies Indirect Fluorescent Antibody Test

Published on: January 19, 2024

Related Experiment Videos

Last Updated: May 30, 2026

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

Detection of Rabies IgG and IgM Antibodies Using the Rabies Indirect Fluorescent Antibody Test

Detection of Rabies IgG and IgM Antibodies Using the Rabies Indirect Fluorescent Antibody Test

Published on: January 19, 2024

Area of Science:

Virology
Immunology
Public Health

Background:

Accurate identification of recent human immunodeficiency virus (HIV) antibody seroconversion is vital for effective treatment, research, and prevention strategies.
However, the diagnostic accuracy, specifically sensitivity and specificity, of available tests for recent HIV infection remains uncertain.

Purpose of the Study:

To evaluate the sensitivity and specificity of antibody-based methods for classifying individuals within specific timeframes (30, 60, or 90 days) of HIV seroconversion.
To compare the performance of standard enzyme immunoassays (EIAs), a less-sensitive EIA (LS-EIA), the BED assay, and Western blot (WB) assays for recent HIV infection detection.

Main Methods:

Longitudinal serum panels from 155 individuals with documented pre-seroconversion status were analyzed.
Performance metrics including sensitivity, specificity, and area under the receiver operator characteristic curves (AUROC) were calculated for each assay at different time points post-seroconversion.

Main Results:

Standard EIAs and Western blots demonstrated high specificity (98%-100%) but variable sensitivity (34%-58%) for detecting infections within 30 days.
The LS-EIA and BED assay showed improved sensitivity (84%-88%) with moderate specificity (72%-73%) for the 30-day window.
The BED assay performed best for identifying infections within 90 days (AUROC 0.86), while LS-EIA and BED assay were optimal for the 60-day window (AUROC 0.85).

Conclusions:

Standard EIAs, Western blots, and HIV incidence assays, including the BED assay, provide valuable data for identifying individuals in the early stages of HIV infection (30-90 days post-seroconversion).
Assay selection should consider the specific time window of interest and the balance between sensitivity and specificity required for public health objectives.